RA Session II, Taysha Gene Therapies CEO

Pre­lude to buy­out? Astel­las picks up Taysha stock, two gene ther­a­py pro­grams for $50M

Half a year af­ter Taysha Gene Ther­a­pies laid off 35% of its staffers and paused the bulk of its R&D work, the Dal­las crew has se­cured a part­ner — and some cash — to sup­port two main pro­grams re­main­ing in the pipeline.

Astel­las is swoop­ing in to ac­quire 15% of the biotech as well as an op­tion to ex­clu­sive­ly li­cense TSHA-102 for Rett syn­drome and TSHA-120 for gi­ant ax­on­al neu­ropa­thy (GAN). The to­tal in­vest­ment comes to $50 mil­lion, a mod­est sum that re­flects the fi­nan­cial predica­ment Taysha found it­self in.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.